Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00324766
Recruitment Status : Completed
First Posted : May 11, 2006
Last Update Posted : June 26, 2012
Information provided by (Responsible Party):
Oslo University Hospital

Brief Summary:
The purpose of this study is to determine the safety and efficacy of a 24 hour infusion with levosimendan in patients with acute myocardial infarction and heart failure after acute percutaneous coronary intervention (PCI) treatment.

Condition or disease Intervention/treatment Phase
Myocardial Infarction Heart Failure Cardiogenic Shock Drug: levosimendan Drug: placebo, Phase 4

Detailed Description:
Double blind placebo-controlled study with parallel groups in patients with acute PCI treated myocardial infarction complicated with decompensated heart failure. The study include a prospectively defined subgroup of patients in cardiogenic shock. Treating acute myocardial infarction with PCI restores blood flow, but decreased contractility remains for hours and days due to stunned myocardium. Levosimendan has both inotropic and vasodilatory effects which could support the failing heart after treating the acute myocardial infarction with PCI and may improve myocardial stunning and decrease pro-inflammatory cytokines. Levosimendan could improve myocardial contractility, symptoms and outcome without adverse effects. The aims of the study are to investigate whether a 24 hour infusion with levosimendan could improve regional contractility measured by echocardiography, improve BNP levels, reduce the levels of pro-inflammatory cytokines and improve symptoms in patients with acute decompensated heart failure during the first 24 hours after acute PCI.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure.
Study Start Date : June 2006
Actual Primary Completion Date : September 2011
Actual Study Completion Date : March 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1
Drug: levosimendan
1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
Other Name: Simdax

Placebo Comparator: 2
Placebo, 1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
Drug: placebo,
24 h, infusion
Other Name: placebo

Primary Outcome Measures :
  1. Efficacy: Changes in regional contractility measured as wall-motion score index, proBNP and clinical symptoms. [ Time Frame: At 5 days ]
    Changes in regional contractility (WMSI) measured by echo is the primary endpoint in the study and the sample size calculation is based on expected differenced in WMSI from baseline to day 5 between groups.

Secondary Outcome Measures :
  1. Mace: Time to death, non-fatal myocardial infarction or revascularization during the first 6 weeks and 6 months. [ Time Frame: 6 months ]
  2. Time to rehospitalisation for decompensated heart failure. [ Time Frame: 6 months ]
  3. Days hospitalised/days in intensive/coronary care. [ Time Frame: At discharge ]
  4. Changes in inflammation markers. [ Time Frame: 1, 5 days, 6 weeks. ]
  5. Improvement in creatinine clearance. [ Time Frame: 5 days ]
  6. Improvement of hemodynamic parameters. [ Time Frame: 5 days ]
  7. Central venous oxygen saturation. [ Time Frame: 1 day ]
  8. Total mortality. [ Time Frame: 6 months ]
  9. Arrhythmias, hypotension, ischaemic episodes. [ Time Frame: 5 days ]
  10. Change in proBNP [ Time Frame: Baseline to day 5 ]
  11. Change in clinical symptom score [ Time Frame: Baseline to day 5 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Acute ST-elevation myocardial infarction subject to acute PCI or non-ST elevation myocardial infarction subject to PCI within 72 hours after start of chest pain and:
  • Revascularization by PCI,
  • Signs of decreased wall-motion in at least 3 of 16 segments of the left ventricle
  • Dyspnoea at rest and one of the following:

pulmonary edema, pulmonary congestion,need for CPAP or ventilator, need for IC diuretics or oliguria.

Subgroup of patients in cardiogenic shock: Systolic BP below 90 after 1 hour of volume therapy.

Exclusion Criteria:

  • Age below 20 years
  • Heart rate above 120 bpm
  • Septic shock
  • ARDS
  • Creatinine >450 micromol/l
  • Hepatic impairment
  • Significant mechanical outlet obstruction
  • Allergy against study drug medication
  • Anaemia (Hb <8 g/dl)
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00324766

Layout table for location information
Department of Cardiology, Ulleval University Hospital
Oslo, Norway, N-0852
Sponsors and Collaborators
Oslo University Hospital
Layout table for investigator information
Principal Investigator: Trygve Husebye, MD, Department of Cardiology, Ulleval University Hospital
Study Chair: Geir Ø Andersen, MD, PhD Department of Cardiology, Ulleval University Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Oslo University Hospital Identifier: NCT00324766    
Other Study ID Numbers: 0105
First Posted: May 11, 2006    Key Record Dates
Last Update Posted: June 26, 2012
Last Verified: June 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Myocardial Infarction
Shock, Cardiogenic
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Myocardial Ischemia
Vascular Diseases
Cardiotonic Agents
Vasodilator Agents
Phosphodiesterase 3 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs